Gantenerumab

Gantenerumab is a monoclonal antibody for the treatment of Alzheimer's disease. A phase I clinical trial has been conducted in 2006/07. Gantenerumab is a monoclonal antibody for the treatment of Alzheimer's disease. A phase I clinical trial has been conducted in 2006/07. Gantenerumab is currently being evaluated in a prodromal Alzheimer's disease population in the Scarlet Road study, a global phase II study of approximately 360 subjects in 100 centers in 15 countries. One clinical study was stopped on December 19, 2014 after disappointing results. As of late 2014, Phase III clinical trials are ongoing.